SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY ARTICLE M impact

BDSX: Roth Initiates Buy

Roth Capital initiates coverage on Biodesix with a Buy rating and a price target of $32

BDSX

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ: BDSX ) with a Buy rating and announces Price Target of $32.